Although tamoxifen therapy is a very effective treatment for women with ERα-positive breast tumors by inhibiting the ER pathway, this therapy exerts very low effects in some patients with de novo resistance or acquired resistance. This evidence concerns the gene ESR1 and breast neoplasm.